HAS-BLED Bleeding Risk Score
Der HAS-BLED-Score schätzt das jährliche Risiko für schwere Blutungen (Major Bleeds) bei Patienten mit nicht-valvulärem Vorhofflimmern (AF) unter einer Antikoagulation mit Warfarin / Vitamin-K-Antagonisten ein.
• 0 Punkte: Geringes Risiko (Low) – Jährliches Blutungsrisiko: 1,13%
• 1 Punkt: Geringes Risiko (Low) – Jährliches Blutungsrisiko: 1,02%
• 2 Punkte: Mittleres Risiko (Intermediate) – Jährliches Blutungsrisiko: 1,88%
• 3 Punkte: Hohes Risiko (High) – Jährliches Blutungsrisiko: 3,74%
• 4 Punkte: Hohes Risiko (High) – Jährliches Blutungsrisiko: 8,70%
• ≥ 5 Punkte: Hohes Risiko (High) – Jährliches Blutungsrisiko: 12,50%
Rechtlicher Hinweis: Dieser Rechner dient ausschließlich zu Informationszwecken und als klinische Orientierungshilfe. Er ersetzt keine eigenständige ärztliche Beurteilung und medizinische Diagnose.
Referenzen:
1. Pisters R, Lane DA, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-100.
2. Apostolakis S, Lane DA, et al. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost. 2013; 110: 1074-9.
3. Yoshida R, Ishii H, et al. Performance of HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS risk score for predicting long-term bleeding events in patients taking an oral anticoagulant undergoing percutaneous coronary intervention. Journal of Cardiology. 2018.
4. Proietti M, Rivera-Caravaca JM, et al. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores. J Am Heart Assoc. 2018; 7: e009766.
5. Chao TF, Lip GYH, et al. Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors. Thromb Haemost. 2018; 118: 768-77.
6. Lip GY, Lin HJ, et al. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: The Chin-Shan Community Cohort Study. International Journal of Cardiology. 2013.
7. Brown JD, Goodin AJ, et al. Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS-BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment. J Am Heart Assoc. 2018; 7.
8. Borre ED, Goode A, et al. Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. Thromb Haemost. 2018; 118: 2171-87.
9. Chao TF, Lip GYH, et al. Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors. Thromb Haemost. 2018; 118: 768-77.
11. Lip GYH, Banerjee A, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018; 154: 1121-201.
12. Lip GYH, Skjoth F, et al. The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. Am J Med. 2018; 131: 574 e13- e27.